Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion Inc (ACON) delivers innovative diagnostic solutions for chronic low back pain through its Nociscan SaaS platform, combining MRS technology with AI-driven biomarker analysis. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical advancements, financial milestones, and strategic initiatives.
Access timely press releases covering FDA communications, peer-reviewed study results, and partnership announcements with leading medical institutions. Our curated collection includes earnings reports, technology updates, and market expansion developments critical for evaluating ACON's position in medical imaging innovation.
Bookmark this page for streamlined access to verified information about Nociscan's clinical adoption, intellectual property developments, and evidence-based research outcomes. Stay informed about ACON's progress in transforming spine diagnostics through objective, noninvasive solutions supported by proprietary signal processing algorithms.
Aclarion (NASDAQ: ACON) has received its 24th US patent through a Notice of Allowance from the USPTO. This patent expands the company's ability to use Magnetic Resonance Spectroscopy (MRS) for identifying propionic acid (PA) throughout the body as a potential biomarker for infection and pain. Previously, Aclarion's patents PA identification by MRS to intervertebral discs only.
The company's technology leverages MRS, a capability of common MRI scanners, to analyze chemical biomarkers within soft tissues. While traditional MRS post-processing faces challenges in generating quality data, Aclarion's patented innovations address these limitations, ensuring more reliable spectral data analysis for their Nociscan solution and other MRS applications.
Aclarion (NASDAQ: ACON) has announced Northwestern Medicine as the first site for its pivotal CLARITY trial, designed to demonstrate Nociscan's clinical and economic value in spine surgery. Northwestern Medicine, which led over 6,900 clinical studies with 372,561 participants in 2024, will participate in this groundbreaking randomized controlled trial.
The CLARITY trial is a fully funded, prospective, multi-center study that will evaluate 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain. The study will compare surgical outcomes between surgeons who are blinded and unblinded to Nociscan results. Nociscan is the first evidence-supported SaaS platform that helps physicians distinguish between painful and nonpainful discs in the lumbar spine through MR Spectroscopy and AI technology.
Aclarion (NASDAQ: ACON) has secured nearly $20 million in gross proceeds in 2025 to fully fund its pivotal CLARITY trial, a prospective, randomized, multicenter study designed to validate Nociscan's effectiveness in improving surgical outcomes for chronic low back pain patients.
The CLARITY trial, led by Dr. Nicholas Theodore of Johns Hopkins, will enroll 300 patients across multiple sites. Nociscan is the first evidence-supported SaaS platform that helps physicians identify painful discs in the lumbar spine through MR Spectroscopy and AI, showing a 97% surgical success rate at one-year follow-up when all Nociscan-identified pain-positive discs are treated.
The technology addresses a significant global healthcare challenge, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain.
Aclarion (NASDAQ: ACON) announced its participation in the Selby Spine Conference, where Dr. Sigurd Berven will present the company's NOCISCAN platform. The presentation, titled 'MR Spectroscopy, Augmented Intelligence, and Low Back Pain – A New Gold Standard,' will showcase how NOCISCAN combines MR Spectroscopy with AI to help physicians identify biomarkers associated with disc pain that are invisible on traditional MRI scans.
NOCISCAN is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. This technology addresses a significant global healthcare challenge, as approximately 266 million people worldwide suffer from degenerative spine disease and low back pain. The presentation is scheduled for January 31, 2025, at 5:55 PM in Deer Valley, UT.
Aclarion (NASDAQ: ACON) announced that its Nociscan product is featured in the RSNA Edition of Siemens Healthineers magazine, MAGNETOM Flash. The article showcases how physicians incorporate Nociscan into their clinical practices for chronic low back pain patients. Nociscan is the first evidence-supported SaaS platform that helps physicians noninvasively distinguish between painful and nonpainful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain. The feature will be highlighted at the RSNA annual meeting from December 1-4, 2024, and is expected to serve as a valuable reference for the medical community.
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the upcoming Virtual Investor Summit Microcap Event on November 21st, 2024. The company will deliver a presentation from 3:30 PM to 4:00 PM ET and will be available for one-on-one meetings throughout the day.
The event will showcase 40 micro-cap companies with catalysts and strong market performance. The presentation will be accessible via webcast, and qualified investors can register for complimentary access to participate in live Q&A sessions.
Aclarion (Nasdaq: ACON, ACONW), a healthcare technology company specializing in chronic low back pain location identification through biomarkers and AI algorithms, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group , is scheduled for October 15, 2024.
CEO Brent Ness will represent Aclarion in a fireside chat at 2:00 PM ET. The summit will feature presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology.
Maxim senior analysts will host these sessions, providing insights into the participating companies. Interested parties can reserve their seats for the virtual event through a provided link.
Aclarion, Inc. (Nasdaq: ACON) announced that its Nociscan AI solution played a key role in a study to better understand Modic changes (MC) in chronic low back pain (cLBP) patients. The study, presented at the 50th International Society for the Study of the Lumbar Spine Annual Meeting 2024, utilized Nociscan to measure intradiscal propionic acid (PA) levels adjacent to vertebral endplates with MC.
The research, conducted by the REACH Center at UCSF, aimed to clarify the biopsychosocial mechanisms of cLBP. Results suggest that PA levels may be useful in understanding why some MC patients improve or respond to treatment while others do not. Nociscan's ability to noninvasively quantify chemical biomarkers associated with disc pain could potentially lead to personalized treatment plans for cLBP patients, including the possibility of using antibiotics as a first-line treatment for those with high PA levels.
Aclarion, Inc. (Nasdaq: ACON) has provided a corporate update on their Nociscan AI technology, which aids in identifying chronic low back pain sources. Key milestones include:
1. Three of four largest private UK insurers now cover Nociscan
2. Partnership with ten prominent KOL surgeons in the US
3. Strategic partnership with ATEC to expand KOL network
4. Multiple commercial agreements in key US markets
5. Participation in NIH's BEST Trial with 800+ patients
6. Launch of CLARITY, a flagship clinical study
The company's technology is protected by 23 US patents and 17 international patents. Aclarion aims to establish Nociscan as a standard of care for chronic low back pain, addressing a $134 billion annual healthcare expenditure in the US.
Aclarion (NASDAQ: ACON) has announced the completion of the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. This randomized controlled trial is comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation for 202 patients with chronic low back pain. Nociscan, Aclarion's technology, uses magnetic resonance spectroscopy (MRS) biomarkers to help identify patient improvement following treatment.
The trial began enrolling patients in Q2 2024, with six patients completing Nociscan exams by late August. Aclarion's CEO, Brent Ness, expressed excitement about the trial's progress and Nociscan's potential role in determining optimal treatment options. The company is also involved in other research studies, including trials in Rome and two NIH studies, as it aims to establish Nociscan as the gold standard for disc treatment decisions in low back pain research.
